Pillar5 Pharma, Inc. has acquired the former Pfizer manufacturing site in Arnprior, Ontario from Keata Pharma, Inc. The lead investors in Pillar5 Pharma are Kevin Rampton and Claude Germain, who have assembled a group of investors to establish the new company and supply capital in an effort to ensure the future of the plant.

“We see this as a terrific opportunity,” said Mr. Rampton, “The facility is well equipped and maintained, and there are very experienced production and management teams in place.”

The Arnprior facility currently produces pharmaceutical and consumer products for Canadian and International markets and employs 95 people. John Carkner, who served as manager of the Arnprior facility since 1998, will serve as president and chief executive officer of Pillar5 Pharma.

“I’m pleased in the confidence that our investors have shown in this plant and its people. We have a long history of quality and customer service, and this new beginning with Pillar5 Pharma will allow us to build on that heritage. This new corporate structure will allow us to focus on our customers and the services we provide to create our future success,” Mr. Carkner said.

Click here to find out more about Pillar5 Pharma